Day: December 11, 2024

ROUYN-NORANDA, Quebec, Dec. 11, 2024 (GLOBE NEWSWIRE) — GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange, TTMzero, Düsseldorf and Quotrix Düsseldorf Stock Exchanges and GLBXF – OTCQX International in the US) is pleased to provide additional drill results from Globex’s infill drill program at Globex’s 100% owned Ironwood gold project in Cadillac Township, Quebec, approximately 2.6 km east of the town of Cadillac. As in our recent press release of December 4th, we continue to intersect significant gold mineralization in a pyrite, pyrrhotite arsenopyrite sulphide replacement zone at the nose of an oxide iron formation fold at depths between 9 m and approximately 225 m vertical. The three drill hole assay results reported today are...

Bollinger has delivered and received payment on initial order of B4 TrucksBergey’s Truck Centers, Started in 1924, has a Commercial Truck Footprint with 26 LocationsBergey’s Truck Centers are located in Delaware, Maryland, New Jersey and Pennsylvania.Addition of respected commercial group, with dealerships in Delaware, Maryland, New Jersey and Pennsylvania, increases Bollinger Motors’ national dealer network to over 50 locations BREA, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) — via IBN – Mullen Automotive Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an electric vehicle (“EV”) manufacturer, announces today that its subsidiary, Bollinger Motors (“Bollinger”), has named Bergey’s Truck Centers (“Bergey’s”) as an official Bollinger Motors’ dealer. Bergey’s Truck Centers expands Bollinger Motors’ commercial sales and service...

Presentation to Feature Lead Drug Candidate GT-02287 and Magellan Drug Discovery Platform BETHESDA, Md., Dec. 11, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, Chief Financial Officer and Interim Chief Executive Officer of Gain, will give a corporate presentation at Biotech Showcase 2025, being held January 13-15, 2025, at the Hilton San Francisco Union Square in San Francisco, CA. Date: Tuesday, January 14 Time: 9:30am PT Track: Yosemite A (Ballroom Level) Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking...

VANCOUVER, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) — Foremost Clean Energy Ltd. (NASDAQ: FMST) (CSE: FAT) (“Foremost” or the “Company”), an emerging North American uranium and lithium exploration company, today issued a letter to shareholders from its President and Chief Executive Officer, Jason Barnard. Dear Shareholders, As we end 2024, I wanted to take a moment to reflect on our Company’s achievements over the past year and set out our objectives for the upcoming year and beyond. 2024 has truly been an evolutionary year for Foremost, marked by a series of strategic business developments and key advancements in our asset portfolio. Over the course of the last 12 months, we have successfully negotiated an option agreement with Denison Mines Corp. (TSX: DML, NYSE American: DNN) (“Denison”) for 10 prospective uranium properties...

The overview presentation will review some of the Company’s recent achievements as well as the outlook for upcoming data milestones JERUSALEM, Dec. 11, 2024 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CEO Uzi Sofer and CFO Raphi Levy will present a corporate overview and update at the J.P. Morgan 43rd Annual Healthcare Conference on Thursday, January 16, 2025 at 9:45am PT / 12:45pm ET, in San Francisco, CA, and will host institutional investor meetings at the event.Event: J.P. Morgan 43rd Annual Healthcare ConferenceFormat: Presentation and 1-on-1 MeetingsDate: January 16, 2025Time: 9:45AM PT – 10:25AM PTLocation: Westin St. Francis, San Francisco, CAWebcast: Link...

Celebration, FL, Dec. 11, 2024 (GLOBE NEWSWIRE) — La Rosa Holdings Corp. (NASDAQ: LRHC) (“La Rosa” or the “Company”), a holding company for six agent-centric, technology-integrated, cloud-based, multi-service real estate segments, today announced the opening of its first office in North Carolina. North Carolina continues to demonstrate significant momentum in its real estate market. As of October 2024:Home prices in North Carolina increased by 2.5% year-over-year, reflecting sustained demand and market strength. On average the number of homes sold rose by 4.6%, showcasing growing buyer activity despite higher interest rates. The inventory of homes for sale grew by 19.0%, signaling increased opportunities for buyers.This expansion allows La Rosa to bring its agent-focused model to the state, equipping real estate professionals...

Ness-Ziona, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Israeli Ministry of Health authorized the initiation of an investigator-initiated Phase I trial to evaluate the safety, tolerability and initial efficacy of Allocetra™ for injection into the temporomandibular joint (TMJ) in patients suffering from TMJ osteoarthritis. The study will be conducted by the Rheumatology Unit at Sheba Medical Center in collaboration with the Department of Oral and Maxillofacial Surgery. Notably, Sheba Medical Center was recently ranked among the top 10 hospitals in the world by Newsweek. Dr. Oren Hershkovitz, CEO of Enlivex, commented, “TMJ osteoarthritis is a unique disease that can affect young,...

Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea’s experimental drug, ATRN-119, over a 24-hour daily cycle New regimen potentially optimizes clinical outcomes and strengthens the clinical path forward ATRN-119 is the first macrocyclic ATR inhibitor to enter clinical trials DOYLESTOWN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision oncology company developing innovative therapies for cancers with specific genetic alterations to potentially minimize damage to healthy cells, announced today that the first patient has been dosed at Dose Level 7, evaluating ATRN-119 550 mg twice daily, in the ongoing ABOYA-119 Phase 1/2a clinical trial. The ABOYA-119 trial is evaluating ATRN-119...

ANB032 was well tolerated across all doses with no safety signals observed AD trial and all further investment in ANB032 will be discontinued Anticipate top-line Phase 2b data in rheumatoid arthritis in February 2025 for rosnilimab, a PD-1+ T cell depleter and agonist Funded beyond additional clinical data catalysts including Phase 2 data in ulcerative colitis for rosnilimab and Phase 1b data for ANB033 and ANB101 Year-end 2024 cash of approximately $415 million and extending cash runway guidance through year-end 2027, excluding potential GSK milestones and royaltiesSAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that investigational ANB032, a BTLA agonist, did not meet the primary and...